Articles By Jof Enriquez
-
NIH Artificial Pancreas Pivotal Trials Get Underway
2/8/2017
The National Institutes of Health (NIH) announced that four NIH-sponsored pivotal clinical trials to test artificial pancreas systems are set to begin in the next two years. The studies are funded by a total of $41 million worth of grants from NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and take closed-loop artificial pancreas systems a step closer to regulatory approval.
-
Baxter Developing New Infusion Pump Platform, Reinvigorating Biosurgery
2/7/2017
Baxter finished its first full year of restructuring with yet another strong quarter. This year, the drug and medical device maker says it can sustain its momentum with the help of its core renal business, as well as a new pump technology under development.
-
Edwards Lifesciences Preps Clinical Trials As TAVR Drives Sales
2/6/2017
Edwards Lifesciences reports that increased uptake of transcatheter heart valves drove up fourth quarter sales by 14 percent, to $768 million. The company expects to implant more of said devices with the ongoing PARTNER III study, and the initiation of EARLY-TAVR trial, which will include patients diagnosed with severe aortic stenosis who have not yet developed symptoms.
-
Is Medtronic Selling Its Medical Supplies Business?
2/2/2017
Medtronic, the world's largest pure-play medical device company, is reportedly in the early stages of selling part or all of the legacy medical supplies business it acquired through its purchase of Covidien more than two years ago.
-
Zimmer Biomet Will Diversify Offerings, Fix Supply Chain In 2017
2/1/2017
Zimmer Biomet will offer an expanded product portfolio and fix product supply chain woes in 2017, as the company tries to build on solid revenue growth in the fourth quarter of 2016.
-
C.R. Bard CEO Outlines Plans For Continued Emerging Market Growth In 2017
1/31/2017
C.R. Bard Inc. posted better-than-expected Q4 2016 results, driven by all four product divisions and strong performance in U.S. and emerging markets. The company plans to increase investments in emerging markets to help sustain its momentum throughout 2017 and beyond.
-
J&J-Google Joint Venture Verb Surgical Unveils Digital Surgery Prototype To Partners
1/30/2017
Verb Surgical — the joint venture between Johnson & Johnson’s Ethicon and Alphabet’s Verily Life Sciences— says it has successfully demonstrated their first digital surgery prototype to senior company executives, one year after announcing their collaboration.
-
Abbott CEO: 2017 Focus Is On Integrating St. Jude, Less M&A
1/27/2017
Abbott this year will concentrate on integrating St. Jude Medical and reducing debt, and will not be as active on the M&A front, according to the company's chief executive.
-
CEO Gorsky: J&J Committed To Diabetes, But Looking To Sell Related Device Business
1/26/2017
Johnson & Johnson CEO Alex Gorsky says the world's largest healthcare company remains "very committed" in the diabetes space, but is exploring the possibility of divesting its diabetes unit as part of a continuing restructuring of its medical device business.
-
German Prosthetics Maker Ottobock Offers Investors Up To 25-Percent Ownership Ahead Of IPO
1/25/2017
German company Ottobock Healthcare GmbH, the world’s largest maker of artificial limbs, is reportedly drawing interest from private equity firms.